Corvus Pharmaceuticals Newsroom

Here's Why We're Not At All Concerned With Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Simply Wall StDec 22 09:56 ET

Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $14

Moomoo NewsDec 20 13:43 ET · Ratings

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $12

Moomoo NewsDec 19 05:31 ET · Ratings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaDec 18 16:06 ET

Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk

WSJDec 18 13:49 ET

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

BenzingaDec 18 13:23 ET

Corvus Falls After Early-stage Data for Eczema Therapy

Seeking AlphaDec 18 08:43 ET

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BenzingaDec 18 08:42 ET

Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

MT NewswiresDec 18 08:31 ET

Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost

TipRanksDec 18 08:00 ET

Express News | Corvus Pharmaceuticals Inc - Lowest Dose Level Cohorts Show Favorable Safety and Efficacy

ReutersDec 18 07:30 ET

Market-Moving News for December 18th

BenzingaDec 18 07:28 ET

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

BenzingaDec 18 04:34 ET

Biggest Stock Movers Wednesday: COMM, HEI, and More

Seeking AlphaDec 18 04:15 ET

Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding

WSJDec 17 18:18 ET

Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal

WSJDec 17 17:53 ET

Express News | Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

ReutersDec 17 16:01 ET

Individual Investors Account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Ownership, While Private Equity Firms Account for 16%

Yahoo FinanceDec 11 07:06 ET

Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity

BenzingaDec 4 16:08 ET

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition With Soquelitinib as a Novel Approach to Modulate Tumor Immunity

GlobeNewswireDec 4 16:05 ET